reported.” data-reactid=”19″>Inovio Pharmaceuticals Inc (NASDAQ: INO) said during the earnings call Monday it expected its COVID-19 vaccine to enter mid-to-late stage human trials in September, Reuters reported.
Inovio said during the earnings call it was exploring partnerships beyond the United States and Europe for its vaccine candidate, and expected repetitive revenue similar to those from the flu vaccine.
The company reiterated its previous estimate of producing one million doses this year and 100 million by 2021, and said it planned to obtain additional external funding to scale up the manufacturing of the vaccine.
Inovio claimed the vaccine could be stored at room temperature for over a year and in normal refrigeration for up to 5 years.
to per course.” data-reactid=”28″>The pricing of the drug would be similar to those of other companies. Rival Moderna Inc’s (NASDAQ: MRNA) is reportedly the steepest priced vaccine at between to per course.
View more earnings on INO” data-reactid=”29″>View more earnings on INO
posted a second-quarter loss of 83 cents per share, compared with loss of 30 cents per share in the same period a year earlier. ” data-reactid=”30″>Q2 Earnings Miss: Inovio posted a second-quarter loss of 83 cents per share, compared with loss of 30 cents per share in the same period a year earlier.
Total revenue was $267,000, compared with $136,000 for the same period in 2019.
Factset analysts had predicted a loss of 17 cents per share and revenue of $2.6 million, MarketWatch reported.
The company attributed the net loss to a derivatives liability, which mandates revaluation at each reporting period. Without this expense, the net loss per share would have been 20 cents, it claimed.
JNJ), Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) are all nearing or already conducting late-stage human trials for their COVID-19 vaccine candidates.
View Article Origin Here
